Redefining Drug Discovery Smarter. Faster. Better.
The success of drug discovery depends on the content of the compound
Since existing libraries are biased
towards historical targets, new protein targets suffer from low hit rates.
Carmolex News: Carmolex, Inc. is proud to announce the launch of its wholly owned European subsidiary,
To break this vicious cycle, CARMOLEX Inc has developed enabling technologies for the large-scale design, synthesis and validation of small molecule protein antagonists, providing the largest chemical libraries available in the world to our clients drug discovery projects.
Carmolex Holdings BV, in the Netherlands.